Dashyant Dhanak - 15 Sep 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role: EVP & Chief Scientific Officer
Signature: /s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 15 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 19 Sep 2023, 16:05:32 UTC
Previous filing: 05 Sep 2023
Next filing: 20 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Award	$0	+65,900		$0.000000	65,900	15 Sep 2023	Direct	F1
transaction	DCPH	Common Stock	Award	$0	+75,000	+114%	$0.000000	140,900	15 Sep 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DCPH	Stock Option (Right to Buy)	Award	$0	+65,900		$0.000000	65,900	15 Sep 2023	Common Stock	65,900	$13.42	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person was awarded 65,900 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in three equal annual installments on each of September 15, 2024, September 15, 2025 and September 15, 2026.
F2	The reporting person was awarded 75,000 RSUs. These RSUs will vest in two equal annual installments on each of September 15, 2024 and September 15, 2025.
F3	This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the shares underlying the option shall vest on September 15, 2024, with the remainder vesting in 36 equal monthly installments thereafter.